American Association of Individual Investors1d
Why Neurogene Inc.’s (NGNE) Stock Is Down 18.34%
Neurogene Inc.’s NGNE share price has dipped by 18.34%, which has investors questioning if this is right time to buy.
Drug treatment extended for Langford girl with rare fatal condition
The family of nine-year-old Charleigh Pollock will continue to be covered for the drug, which costs $1 million a year, until ...
‘This is our child’s life’: B.C. family gets small extension for crucial drug funding
A temporary reprieve for a Vancouver Island family after their terminally-ill daughter will continue to have access to ...
Penticton Western News6d
B.C. resets clock on countdown to end terminal Island girl's drug funding
Provincial funding of 9-year-old Charleigh Pollock's life-sustaining treatment has been extended by 3 months until the end of ...
Q1 Earnings Forecast for Neurogene Issued By Leerink Partnrs
Research analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for Neurogene in a report released on ...
What is William Blair’s Forecast for Neurogene Q1 Earnings?
Stock analysts at William Blair issued their Q1 2025 EPS estimates for Neurogene in a research report issued to clients and ...
American Association of Individual Investors6d
Why Lexeo Therapeutics, Inc.’s (LXEO) Stock Is Down 10.14%
Lexeo Therapeutics, Inc.’s LXEO share price has dipped by 10.14%, which has investors questioning if this is right time to buy.